Blood · 2017 · 271 citations · 20 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyImmunotherapyPharmacodynamicsCancer ImmunotherapyImmunotherapy SafetyMultiple MyelomaPharmacodynamics Of ImmunotherapiesBortezomib TherapyBortezomib-based RegimensBortezomib-based TherapyLenalidomide TherapyRelapse Treatment
expression (59% [16/27]). This novel combination of venetoclax with bortezomib and dexamethasone has an acceptable safety profile and promising efficacy in patients with relapsed/refractory MM. This trial was registered at www.clinicaltrials.gov as #NCT01794507.
20
International uniform response criteria for multiple myeloma
Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations
Medicine, Hematology, Oncology +12
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.9K citations · Full text
Medicine, Cancer Biology, Oncology +14
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo, Asher Chanan‐Khan, Katja Weisel et al. · New England Journal of Medicine · 2016 · 1.5K citations · Full text
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations
Medicine, Oncology, Pharmacology +11